European Growth Companies With High Insider Ownership In October 2026
In October 2026, the European markets have been navigating a complex landscape shaped by geopolitical tensions and fluctuating energy prices, with the pan-European STOXX Europe 600 Index advancing despite these challenges. As investors turn their focus to corporate fundamentals amid the ongoing earnings season, growth companies with high insider ownership can offer unique insights into potential resilience and long-term value in this evolving market environment.
Top 10 Growth Companies With High Insider Ownership In Europe
| Name | Insider Ownership | Earnings Growth |
| Pharma Mar (BME:PHM) | 12.1% | 39.9% |
| Kuros Biosciences (SWX:KURN) | 23.7% | 65.6% |
| KebNi (OM:KEBNI B) | 16.3% | 103.8% |
| Gold Road International (OB:GOLDR) | 36.7% | 89.8% |
| Envipco Holding (ENXTAM:ENVI) | 15.2% | 101.6% |
| CTT Systems (OM:CTT) | 17.4% | 55.3% |
| Clavister Holding AB (publ.) (OM:CLAV) | 19.4% | 41.1% |
| Bonesupport Holding (OM:BONEX) | 10.6% | 32.4% |
| Bergen Carbon Solutions (OB:BCS) | 11.9% | 52% |
| 2G Energy (XTRA:2GB) | 13.4% | 35.4% |
Underneath we present a selection of stocks filtered out by our screen.
Pharma Mar (BME:PHM)
Simply Wall St Growth Rating: ★★★★★★
Overview: Pharma Mar, S.A. is a biopharmaceutical company engaged in the research, development, production, and commercialization of bio-active oncology principles with operations spanning Spain, Germany, Ireland, France, Switzerland, the rest of the European Union, the United States and internationally; it has a market cap of approximately €1.18 billion.
Operations: Pharma Mar generates revenue through its activities in researching, developing, producing, and commercializing bio-active principles for oncology across various regions including Spain, Germany, Ireland, France, Switzerland, other parts of the European Union, the United States, and internationally.
Insider Ownership: 12.1%
Earnings Growth Forecast: 39.9% p.a.
PharmaMar's insider ownership aligns with its growth trajectory, as earnings are projected to grow significantly, outpacing the Spanish market. Recent MHRA approval for Zepzelca in the UK enhances its product portfolio in oncology, potentially boosting revenue. Despite a sharp drop in H1 2026 net income to €0.56 million from €19.42 million a year ago, analysts foresee substantial stock price appreciation and high return on equity over the next three years.
- Click to explore a detailed breakdown of our findings in Pharma Mar's earnings growth report.
- The analysis detailed in our Pharma Mar valuation report hints at an deflated share price compared to its estimated value.
Embracer Group (OM:EMBRAC B)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Embracer Group AB (publ) is an international developer and publisher of PC, console, mobile, VR, and board games with a market capitalization of approximately SEK19.88 billion.
Operations: The company's revenue segments include the development and publishing of PC, console, mobile, VR, and board games for the global gaming market.
Insider Ownership: 11.1%
Earnings Growth Forecast: 96.1% p.a.
Embracer Group's insider ownership supports its growth potential, with earnings forecasted to rise significantly, despite slower revenue growth compared to high-growth benchmarks. Recent financial restructuring includes a SEK 2 billion credit facility, enhancing liquidity and replacing previous loans. The company reported improved Q1 2026 results with net income of SEK 39 million against a prior loss. The board changes and share buybacks reflect strategic adjustments aimed at long-term value creation amid evolving market conditions.
- Navigate through the intricacies of Embracer Group with our comprehensive analyst estimates report here.
- In light of our recent valuation report, it seems possible that Embracer Group is trading behind its estimated value.
Swedencare (OM:SECARE)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Swedencare AB (publ) is involved in the development, manufacturing, marketing, and sale of animal healthcare products for cats, dogs, and horses across North America, Europe, and other international markets with a market cap of SEK3.77 billion.
Operations: The company's revenue segments include SEK702.30 million from Europe, SEK688.80 million from Production, and SEK1.58 billion from North America, with a segment adjustment of -SEK240.50 million.
Insider Ownership: 12%
Earnings Growth Forecast: 45.6% p.a.
Swedencare's robust insider ownership aligns with its growth trajectory, as earnings are forecast to grow significantly faster than the Swedish market. Despite a recent CEO transition, the company maintains strong financial health, reporting a turnaround from loss to net income in Q2 2026. Revenue growth is projected at 9.3% annually, outpacing local market trends. Shares have seen more insider buying than selling recently, although not substantially. The stock trades well below estimated fair value despite low future ROE forecasts.
- Delve into the full analysis future growth report here for a deeper understanding of Swedencare.
- Our expertly prepared valuation report Swedencare implies its share price may be lower than expected.
Where To Now?
- Dive into all 206 of the Fast Growing European Companies With High Insider Ownership we have identified here.
- Ready To Venture Into Other Investment Styles? Explore 25 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com